Is Twist Bioscience Stock a Good Investment?
Twist Bioscience Investment Advice | TWST |
- Examine Twist Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Twist Bioscience's leadership team and their track record. Good management can help Twist Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Twist Bioscience's business and its evolving consumer preferences.
- Compare Twist Bioscience's performance and market position to its competitors. Analyze how Twist Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Twist Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Twist Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Twist Bioscience Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Twist Bioscience Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Twist Bioscience Stock
Researching Twist Bioscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.38. Twist Bioscience Corp had not issued any dividends in recent years.
To determine if Twist Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Twist Bioscience's research are outlined below:
| Twist Bioscience generated a negative expected return over the last 90 days | |
| Twist Bioscience has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 312.97 M. Net Loss for the year was (208.73 M) with profit before overhead, payroll, taxes, and interest of 147.23 M. | |
| Twist Bioscience Corp currently holds about 504.97 M in cash with (64.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.93. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Twist Biosciences Dennis Cho sells 9,585 in common stock - Investing.com |
Twist Bioscience Quarterly Good Will |
|
Twist Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Twist Bioscience Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Twist Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Twist Bioscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Twist Bioscience's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-05-07 | 2020-03-31 | -0.75 | -0.85 | -0.1 | 13 | ||
2019-08-01 | 2019-06-30 | -0.82 | -0.92 | -0.1 | 12 | ||
2024-11-15 | 2024-09-30 | -0.6933 | -0.59 | 0.1033 | 14 | ||
2025-01-31 | 2024-12-31 | -0.635 | -0.53 | 0.105 | 16 | ||
2023-11-17 | 2023-09-30 | -0.92 | -0.81 | 0.11 | 11 | ||
2019-12-11 | 2019-09-30 | -0.83 | -0.96 | -0.13 | 15 | ||
2022-05-05 | 2022-03-31 | -1.28 | -1.13 | 0.15 | 11 | ||
2022-02-04 | 2021-12-31 | -1.06 | -0.91 | 0.15 | 14 |
Twist Bioscience Target Price Consensus
Twist target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Twist Bioscience's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Twist analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Twist stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Twist Bioscience Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTwist Bioscience Target Price Projection
Twist Bioscience's current and average target prices are 44.27 and 52.14, respectively. The current price of Twist Bioscience is the price at which Twist Bioscience Corp is currently trading. On the other hand, Twist Bioscience's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Twist Bioscience Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Twist Bioscience Target Price
Twist Bioscience Analyst Ratings
Twist Bioscience's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Twist Bioscience stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Twist Bioscience's financials, market performance, and future outlook by experienced professionals. Twist Bioscience's historical ratings below, therefore, can serve as a valuable tool for investors.Know Twist Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Twist Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Twist Bioscience Corp backward and forwards among themselves. Twist Bioscience's institutional investor refers to the entity that pools money to purchase Twist Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-12-31 | 1.4 M | Geode Capital Management, Llc | 2024-12-31 | 1.4 M | First Light Asset Management, Llc | 2024-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 899.2 K | Goldman Sachs Group Inc | 2024-12-31 | 895.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 879 K | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 853.7 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 846.1 K | Tao Capital Management Lp | 2024-12-31 | 828.8 K | Artisan Partners Limited Partnership | 2024-12-31 | 5.9 M | Vanguard Group Inc | 2024-12-31 | 5.8 M |
Twist Bioscience's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.68 B.Market Cap |
|
Twist Bioscience's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.37) | (0.38) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.51) | (0.48) |
Determining Twist Bioscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Twist Bioscience is a good buy. For example, gross profit margin measures Twist Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Twist Bioscience's profitability and make more informed investment decisions.
Twist Bioscience's Earnings Breakdown by Geography
Please note, the imprecision that can be found in Twist Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Twist Bioscience Corp. Check Twist Bioscience's Beneish M Score to see the likelihood of Twist Bioscience's management manipulating its earnings.
Evaluate Twist Bioscience's management efficiency
Twist Bioscience Corp has return on total asset (ROA) of (0.1524) % which means that it has lost $0.1524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3773) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.38 in 2025. Return On Capital Employed is likely to drop to -0.38 in 2025. Non Current Liabilities Total is likely to gain to about 86.5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.33 | 7.70 | |
| Tangible Book Value Per Share | 5.78 | 2.94 | |
| Enterprise Value Over EBITDA | (16.14) | (16.95) | |
| Price Book Value Ratio | 4.99 | 5.24 | |
| Enterprise Value Multiple | (16.14) | (16.95) | |
| Price Fair Value | 4.99 | 5.24 | |
| Enterprise Value | 555.1 M | 493.4 M |
Leadership at Twist Bioscience emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 2.146 |
Basic technical analysis of Twist Stock
As of the 25th of March, Twist Bioscience has the Risk Adjusted Performance of (0.0001), variance of 15.89, and Coefficient Of Variation of (11,470). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Twist Bioscience Corp, as well as the relationship between them.Twist Bioscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Twist Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Twist Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Twist Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Twist Bioscience's Outstanding Corporate Bonds
Twist Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Twist Bioscience Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Twist bonds can be classified according to their maturity, which is the date when Twist Bioscience Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Twist Bioscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Twist Bioscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.0001) | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.12 | |||
| Coefficient Of Variation | (11,470) | |||
| Standard Deviation | 3.99 | |||
| Variance | 15.89 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0241 | |||
| Total Risk Alpha | 0.1164 | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 18.27 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 6.39 | |||
| Skewness | (0.05) | |||
| Kurtosis | (0.23) |
| Risk Adjusted Performance | (0.0001) | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.12 | |||
| Coefficient Of Variation | (11,470) | |||
| Standard Deviation | 3.99 | |||
| Variance | 15.89 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0241 | |||
| Total Risk Alpha | 0.1164 | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 18.27 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 6.39 | |||
| Skewness | (0.05) | |||
| Kurtosis | (0.23) |
Consider Twist Bioscience's intraday indicators
Twist Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Twist Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 21696.61 | |||
| Daily Balance Of Power | (0.46) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 44.12 | |||
| Day Typical Price | 44.17 | |||
| Price Action Indicator | (0.18) | |||
| Period Momentum Indicator | (0.67) |
Twist Bioscience Corporate Filings
F4 | 24th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of March 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify | |
8K | 3rd of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Twist Stock media impact
Far too much social signal, news, headlines, and media speculation about Twist Bioscience that are available to investors today. That information is available publicly through Twist media outlets and privately through word of mouth or via Twist internal channels. However, regardless of the origin, that massive amount of Twist data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Twist Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Twist Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Twist Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Twist Bioscience alpha.
Twist Bioscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Twist Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Twist Bioscience Corp Historical Investor Sentiment
Investor biases related to Twist Bioscience's public news can be used to forecast risks associated with an investment in Twist. The trend in average sentiment can be used to explain how an investor holding Twist can time the market purely based on public headlines and social activities around Twist Bioscience Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Twist Bioscience's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Twist Bioscience and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Twist Bioscience news discussions. The higher the estimate score, the more favorable the investor's outlook on Twist Bioscience.
Twist Bioscience Maximum Pain Price Across May 16th 2025 Option Contracts
Twist Bioscience's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Twist Bioscience close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Twist Bioscience's options.
Twist Bioscience Corporate Management
| Dennis JD | Chief VP | Profile | |
| William Banyai | GM Development | Profile | |
| Kevin Yankton | VP Officer | Profile | |
| Chet Gandhi | Chief Officer | Profile | |
| Michael Fero | Chief Officer | Profile |
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.